RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $18
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $16 to $18.
RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $16 to $18.